1.5 mg retatrutide for Weight Loss: TRIUMPH-1 Results, Cost, Insurance Retatrutide Research Peptide | Dakota

Blood 117 , 54385448 (2011)

Among Medicare-eligible adults considering GLP-1 therapy, the highest-risk subgroups for adverse outcomes from inadequately monitored weight loss include: Adults 75 and older, particularly those with pre-existing frailty or recent unintentional weight loss Postmenopausal women with pre-existing osteopenia or osteoporosis who are not on bone-protective therapy Adults with pre-existing sarcopenia identified by prior weakness, gait slowing, or history of falls People with low protein intake due to food insecurity, dental problems, or swallowing difficulties Those taking multiple medications that interact with the cardiovascular effects of rapid weight loss, including antihypertensives and diuretics that may require dose adjustments as weight decreases Symptoms and Warning Signs to Watch For Older adults beginning GLP-1 therapy should watch for and report the following to their prescribing physician promptly: Rapid or unexpected weight loss (more than 1.5 kg or 3.3 lbs per week) Increased weakness, difficulty rising from a chair without arm support, or balance problems Falls or near-falls Reduced grip strength or difficulty with tasks requiring hand strength Poor appetite or inability to meet daily protein targets despite nutritional counseling Any fracture following minimal trauma What You Can Do Now For Medicare beneficiaries considering the GLP-1 Bridge Program: Before starting, ask your physician to assess your current muscle mass and strength

Jurkowska was supported by a Mobility Plus fellowship from the Ministry of Science and Higher Education (MNISW), Republic of Poland

Tirzepatide versus semaglutide for weight loss in overweight and obese adults: A systematic review and meta-analysis of direct comparative studies

Epigenetic histone modification by butyrate downregulates KIT and attenuates mast cell function